Research Analysts Offer Predictions for Axsome Therapeutics, Inc.'s Q3 2025 Earnings (NASDAQ:AXSM)

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Investment analysts at HC Wainwright dropped their Q3 2025 EPS estimates for Axsome Therapeutics in a report released on Tuesday, May 7th. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.47 per share for the quarter, down from their prior estimate of $0.51. HC Wainwright currently has a "Buy" rating and a $190.00 price target on the stock. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($3.75) per share. HC Wainwright also issued estimates for Axsome Therapeutics' Q4 2025 earnings at $1.33 EPS.

Other analysts have also recently issued reports about the company. Guggenheim upped their price objective on Axsome Therapeutics from $110.00 to $125.00 and gave the stock a "buy" rating in a report on Wednesday, February 21st. Royal Bank of Canada lifted their price objective on shares of Axsome Therapeutics from $123.00 to $128.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 26th. Citigroup lowered their price objective on shares of Axsome Therapeutics from $127.00 to $125.00 and set a "buy" rating for the company in a research note on Tuesday. Piper Sandler raised their target price on shares of Axsome Therapeutics from $90.00 to $113.00 and gave the stock an "overweight" rating in a report on Tuesday, January 16th. Finally, UBS Group started coverage on shares of Axsome Therapeutics in a report on Tuesday, February 6th. They set a "buy" rating and a $111.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $121.92.

Axsome Therapeutics Price Performance

Axsome Therapeutics stock traded down $2.00 during midday trading on Thursday, reaching $73.68. 1,070,736 shares of the stock traded hands, compared to its average volume of 713,508. The stock has a market cap of $3.50 billion, a P/E ratio of -11.55 and a beta of 1.13. The stock's fifty day moving average is $73.84 and its 200-day moving average is $75.72. The company has a quick ratio of 3.52, a current ratio of 3.63 and a debt-to-equity ratio of 0.93. Axsome Therapeutics has a 12 month low of $55.02 and a 12 month high of $98.40.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings data on Tuesday, February 20th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($1.21) by $0.48. Axsome Therapeutics had a negative net margin of 88.41% and a negative return on equity of 70.67%. The business had revenue of $71.53 million during the quarter, compared to the consensus estimate of $70.38 million.

Hedge Funds Weigh In On Axsome Therapeutics

Several large investors have recently made changes to their positions in the stock. Washington Trust Advisors Inc. acquired a new stake in Axsome Therapeutics during the 4th quarter worth approximately $26,000. Fifth Third Bancorp grew its position in Axsome Therapeutics by 100.0% in the 3rd quarter. Fifth Third Bancorp now owns 400 shares of the company's stock valued at $28,000 after buying an additional 200 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Axsome Therapeutics by 5,550.0% in the first quarter. Russell Investments Group Ltd. now owns 791 shares of the company's stock valued at $63,000 after acquiring an additional 777 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in Axsome Therapeutics by 110.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,204 shares of the company's stock worth $84,000 after purchasing an additional 633 shares during the period. Finally, Janiczek Wealth Management LLC acquired a new position in Axsome Therapeutics during the 1st quarter worth approximately $97,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, COO Mark L. Jacobson sold 24,662 shares of the business's stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $77.24, for a total transaction of $1,904,892.88. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Axsome Therapeutics news, Director Roger Jeffs sold 29,976 shares of the business's stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $69.70, for a total value of $2,089,327.20. Following the transaction, the director now directly owns 120,756 shares in the company, valued at approximately $8,416,693.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Mark L. Jacobson sold 24,662 shares of the company's stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $77.24, for a total transaction of $1,904,892.88. The disclosure for this sale can be found here. 24.50% of the stock is currently owned by company insiders.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.